Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NKTR Nektar Therapeutics	$0.65 -5.1%	$0.84	$0.64 ▼ $1.93	$119.29M	0.65	1.89 million shs	1.33 million shs
OMER Omeros	$7.93 -3.5%	$8.66	$2.61 ▼ $13.60	$459.54M	2.03	526,508 shs	950,026 shs
PCRX Pacira BioSciences	$24.35 -2.0%	$24.81	$11.16 ▼ $31.67	$1.13B	0.86	933,238 shs	227,941 shs
SUPN Supernus Pharmaceuticals	$31.65 -3.4%	$35.05	$25.53 ▼ $40.28	$1.78B	0.83	476,923 shs	218,724 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NKTR Nektar Therapeutics	-8.11%	-20.99%	-19.34%	-26.88%	-27.21%
OMER Omeros	-2.95%	-8.87%	-2.26%	-16.80%	+138.26%
PCRX Pacira BioSciences	-0.24%	+0.04%	+3.33%	+31.90%	-14.96%
SUPN Supernus Pharmaceuticals	+1.42%	+0.15%	+2.15%	-9.43%	-3.99%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NKTR Nektar Therapeutics	4.2721 of 5 stars	3.5	3.0	4.2	2.7	2.5	0.6
OMER Omeros	3.5967 of 5 stars	3.4	0.0	4.4	2.6	1.7	0.6
PCRX Pacira BioSciences	3.6509 of 5 stars	3.2	1.0	3.9	2.3	2.5	0.6
SUPN Supernus Pharmaceuticals	2.7655 of 5 stars	2.2	3.0	4.1	2.1	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NKTR Nektar Therapeutics	3.00	Buy	$4.92	662.27% Upside
OMER Omeros	2.80	Moderate Buy	$22.50	183.73% Upside
PCRX Pacira BioSciences	2.33	Hold	$27.22	11.80% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	13.75% Upside

Current Analyst Ratings Breakdown

Latest OMER, SUPN, PCRX, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/1/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/21/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/14/2025	NKTR Nektar Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$6.00
3/13/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/13/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.50 ➝ $6.50
2/28/2025	PCRX Pacira BioSciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $24.00
2/28/2025	PCRX Pacira BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$57.00 ➝ $70.00
2/28/2025	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00 ➝ $32.00
2/26/2025	SUPN Supernus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $36.00
2/25/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform

(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NKTR Nektar Therapeutics	$98.43M	1.22	N/A	N/A	$0.69 per share	0.93
OMER Omeros	N/A	N/A	N/A	N/A	($0.40) per share	N/A
PCRX Pacira BioSciences	$700.97M	1.61	$3.75 per share	6.50	$18.74 per share	1.30
SUPN Supernus Pharmaceuticals	$661.82M	2.67	$1.45 per share	21.83	$16.87 per share	1.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NKTR Nektar Therapeutics	-$276.06M	-$0.59	N/A	N/A	N/A	-180.70%	-173.28%	-46.31%	5/8/2025 (Estimated)
OMER Omeros	-$117.81M	-$2.31	N/A	N/A	N/A	N/A	N/A	-49.92%	5/21/2025 (Estimated)
PCRX Pacira BioSciences	$41.96M	-$2.19	N/A	9.47	N/A	-13.07%	13.42%	7.19%	5/6/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$1.32M	$1.32	29.78	21.98	N/A	9.16%	7.79%	5.67%	5/6/2025 (Estimated)

Latest OMER, SUPN, PCRX, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/7/2025	N/A	OMER Omeros	-$0.71	N/A	N/A	N/A	N/A	N/A
3/12/2025	Q4 2024	NKTR Nektar Therapeutics	-$0.18	$0.15	+$0.33	$0.03	$36.65 million	$29.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NKTR Nektar Therapeutics	N/A	4.24	4.24
OMER Omeros	N/A	2.96	2.96
PCRX Pacira BioSciences	0.51	2.25	1.89
SUPN Supernus Pharmaceuticals	N/A	2.20	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NKTR Nektar Therapeutics	75.88%
OMER Omeros	48.79%
PCRX Pacira BioSciences	99.73%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
NKTR Nektar Therapeutics	3.71%
OMER Omeros	12.30%
PCRX Pacira BioSciences	6.40%
SUPN Supernus Pharmaceuticals	9.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NKTR Nektar Therapeutics	220	186.10 million	177.62 million	Optionable
OMER Omeros	210	57.95 million	50.82 million	Optionable
PCRX Pacira BioSciences	720	46.28 million	43.22 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.81 million	50.08 million	Optionable

OMER, SUPN, PCRX, and NKTR Headlines

Recent News About These Companies

SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Supernus Pharmaceuticals, Inc. Investment

April 1 at 7:30 AM | accessnewswire.com

An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses.

March 31 at 7:25 AM | accessnewswire.com

Sei Investments Co. Sells 16,825 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

March 31 at 3:53 AM | marketbeat.com

41,700 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by KLP Kapitalforvaltning AS

March 30 at 4:03 AM | marketbeat.com

Loomis Sayles & Co. L P Has $53.05 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

March 29 at 5:39 AM | marketbeat.com

American Century Companies Inc. Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

March 29 at 4:10 AM | marketbeat.com

SUPN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc.

March 28, 2025 | accessnewswire.com

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

March 27, 2025 | msn.com

ATTENTION SUPN SHAREHOLDERS: Investors who lost money on Supernus Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

March 27, 2025 | accessnewswire.com

Supernus Pharmaceuticals, Inc. (SUPN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

March 26, 2025 | accessnewswire.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to "Buy" Rating by StockNews.com

March 25, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. Being Investigated on Behalf of Supernus Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.

March 25, 2025 | accessnewswire.com

11,282 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Proficio Capital Partners LLC

March 25, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Supernus Pharmaceuticals, Inc. (SUPN)

March 24, 2025 | accessnewswire.com

Raymond James Financial Inc. Takes $6.85 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

March 24, 2025 | marketbeat.com

Fox Run Management L.L.C. Makes New $1.30 Million Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

March 23, 2025 | marketbeat.com

12,938 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by Royce & Associates LP

March 23, 2025 | marketbeat.com

SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on Your Supernus Pharmaceuticals, Inc. Investment

March 21, 2025 | accessnewswire.com

Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

March 20, 2025 | accessnewswire.com

Levi & Korsinsky Announces an Investigation on Behalf of Supernus Pharmaceuticals, Inc. (SUPN) Shareholders Who May Have Been Affected by Fraud

March 19, 2025 | accessnewswire.com

Investors who lost money on Supernus Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - SUPN

March 18, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story?
By Leo Miller | March 28, 2025
View How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story?

OMER, SUPN, PCRX, and NKTR Company Descriptions

Nektar Therapeutics NASDAQ:NKTR

$0.64 -0.04 (-5.15%)

As of 02:25 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Omeros NASDAQ:OMER

$7.90 -0.32 (-3.88%)

As of 02:25 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Pacira BioSciences NASDAQ:PCRX

$24.35 -0.50 (-2.01%)

As of 02:24 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Supernus Pharmaceuticals NASDAQ:SUPN

$31.63 -1.12 (-3.41%)

As of 02:25 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time